Taleb Andia, Afshari Mahdi, Samzadeh Mohammad, Sarhangi Negar, Nafar Mohsen, Hasanzad Mandana
Medical Genomics Research Center, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.
Department of Community Medicine, Zabol University of Medical Sciences, Zabol, Iran.
J Diabetes Metab Disord. 2021 Dec 2;21(1):69-75. doi: 10.1007/s40200-021-00936-7. eCollection 2022 Jun.
The most effective and common treatment for end-stage renal disease is kidney transplantation.The personalized approach to kidney transplantation, which utilizes precision medicine principles, determines distinctive genomics characteristics of candidates/recipients that must be taken into account. may be a suitable candidate gene for studying allograft rejection. The aim of this study was to understand whether we can consider two common variants of the gene as a risk factor of transplant rejection in a group of Iranian population.
Totally, 169 kidney transplant recipients, including acute rejections (N=39) and non-rejection (N=130) groups who underwent transplantation were included in this study. The genotyping of rs5742909 (-318C/T) and rs231775 (+49A/G) variants of the gene were performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique.
The AG genotype frequency of rs231775 variant was the same in both patients with and without a history of rejection while, none of those groups had homozygote genotype. In rs5742909, both CT and TT frequencies of patients with rejected transplant were lower than patients with a normal outcome.
The results of the presented study suggest that rs231775 and rs5742909 of genetic variants are not linked to acute rejection who underwent kidney transplantation. So, these variants cannot be considered as risk factors of acute allograft rejection in a group of Iranian renal transplantation recipients. However, the transplantation precision medicine may be an important area for the improvement of patients outcome as the precision medicine has already entered clinical practice in kidney transplantation.
终末期肾病最有效且常见的治疗方法是肾移植。利用精准医学原则的肾移植个性化方法,确定了候选者/受者必须考虑的独特基因组特征。 可能是研究移植排斥反应的合适候选基因。本研究的目的是了解在一组伊朗人群中,我们是否可以将该基因的两个常见变体视为移植排斥反应的危险因素。
本研究共纳入169例接受移植的肾移植受者,包括急性排斥反应组(N = 39)和无排斥反应组(N = 130)。采用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术对该基因的rs5742909(-318C/T)和rs231775(+49A/G)变体进行基因分型。
rs231775变体的AG基因型频率在有和无排斥反应史的患者中相同,且两组均无纯合子基因型。在rs5742909中,移植排斥患者的CT和TT频率均低于结局正常的患者。
本研究结果表明,该基因变体的rs231775和rs5742909与接受肾移植的急性排斥反应无关。因此,在一组伊朗肾移植受者中,这些变体不能被视为急性移植排斥反应的危险因素。然而,由于精准医学已在肾移植中进入临床实践,移植精准医学可能是改善患者结局的重要领域。